Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$236.97 USD

236.97
597,597

-1.09 (-0.46%)

Updated Oct 3, 2024 03:59 PM ET

After-Market: $232.00 -4.97 (-2.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 252)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?

We are upbeat about Varian Medical's oncology business that accounted for around 95% of the company's total revenue in fourth-quarter 2017.

    Baxter International (BAX) Q3 Earnings: What's in Store?

    Baxter International Inc's (BAX) third quarter estimate revision trend is encouraging due to acquisitions and strategic collaborations to enhance its product portfolio.

      Walgreens Boots (WBA) to Report Q4 Earnings: What's in Store?

      Walgreens Boots (WBA) may witness another quarter of prescription growth and strength in Retail Pharmacy USA division in Q4 earnings.

        Can Illumina (ILMN) Maintain Balanced Growth in Q3 Earnings?

        Illumina (ILMN) might gain from continued growth in Product as well as Service and other segments in the third quarter.

          Will Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings?

          Edwards Lifesciences (EW) will likely ride high in Q3 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve Therapy space.

            Will Recall Issue Hurt Boston Scientific (BSX) Q3 Earnings?

            Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.

              Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings?

              Nutrisystem's (NTRI) innovative products are expected to expand customer base that will eventually drive reactivation revenues in Q3.

                What to Expect From Thermo Fisher (TMO) in Q3 Earnings

                Thermo Fisher (TMO) gears up for another quarter of strong analytical instruments segmental growth. Improvement is likely to be seen in applied markets too.

                  Will Intuitive Surgical (ISRG) Disappoint in Q3 Earnings?

                  We believe that the growing adoption of Intuitive Surgical's (ISRG) da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a catalyst for the quarter.

                    Can CR Bard (BCR) Spring a Surprise This Earnings Season?

                    We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon will result in improved performance for CR Bard (BCR) in Q3.

                      Can ResMed (RMD) Maintain Balanced Growth in Q1 Earnings?

                      ResMed (RMD) may ride high in Q1 on continued growth in its domestic as well as overseas business.

                        Kevin Cook headshot

                        $200 Club Bullish Stampede

                        These 5 growth stocks are leading the charge and keeping their promise to hit $200 sooner than even I imagined.

                          Kevin Cook headshot

                          Gaming the Stock Market with Poker Smarts

                          Technical analysis and probability skills are essential, but behavioral analysis will take you to the pro's table.

                            Align Technology (ALGN) Prospects Bright, Competition Rife

                            Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.

                              The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard

                              The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard

                                Align Technology at 52-Week High: What's Driving the Stock?

                                Align Technology's (ALGN) efforts to expand worldwide instil confidence in investors. The market is upbeat about the non-exclusive distribution agreement with Patterson Dental.

                                  BioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised)

                                  BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.

                                    Align Technology-Patterson Dental Deal Expands iTero Reach

                                    Align Technology (ALGN) progresses with a slew of developments in the scanners and services segment.

                                      Align Technology's Invisalign Sales Strong Amid Margin Woes

                                      Align Technology's (ALGN) huge InvisAlign prospects in North America and international regions render optimism. However, escalating costs and expenses put pressure on the company's margins.

                                        Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife

                                        Cerner's (CERN) growth in order bookings would continue to boost growth prospects. However, steep competition in the HCIT space raise concern.

                                          Quality Systems Professional Service a Drag, Competition Rife

                                          Quality Systems' (QSII) performance in the professional service business continues to be a drag in recent times. Also, macro headwinds continue to put pressure on performance.

                                            Here's Why You Must Add Chemed (CHE) Stock to Your Portfolio

                                            Chemed Corporation's (CHE) promising Roto-Rooter revenue outlook as well as an increased bottom-line guidance bode well of the company's future.

                                              BioScrip's Infusion Business Strong, Dull 2017 View a Drag

                                              BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.

                                                Stryker (SYK) to Gain From Solid Portfolio and Acquisitions

                                                Stryker's (SYK) diverse product portfolio alongside acquisition-driven strategy would continue to boost growth prospects. However, competition in the Chinese market raise concern.

                                                  Zimmer (ZBH) Plagued by Various Internal and External Issues

                                                  Zimmer Biomet (ZBH) continues to suffer a bad patch, entangled with issues including its decade-old CEO's recent exit post a dull earnings season due to poor knee business.